Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Galapagos News

    27,24 € +0,15% +0,04 €
    19.04.24 21:55:23 Tradegate aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0EAT9
    ISIN: BE0003818359
    US-Symbol: GLPGF
    Typ: Aktie
    Werbung
    Weiter aufwärts?
    Long Hebel 5,95
    ME0PSD

    Ad-hocs

    04.04.24 - GlobeNewswire
    Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
    Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-​Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / ...
    28.03.24 - GlobeNewswire
    Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
    Publication of annual report for financial year 2023 Annual Shareholders’ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board ...
    26.03.24 - GlobeNewswire
    Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
    Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors ...
    22.02.24 - GlobeNewswire
    Galapagos announces full year 2023 results and outlook for 2024
    Full year 2023 key financials :
    15.02.24 - GlobeNewswire
    Galapagos presents at EBMT-EHA annual meeting 2024
    Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies
    31.01.24 - GlobeNewswire
    Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
    Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its ...
    04.01.24 - GlobeNewswire
    Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
    Thermo Fisher Scientific to provide CAR-T manufacturing and kitting services for Galapagos’ point-​of-care CAR-T product candidate in the San Francisco area Agreement follows ...
    03.01.24 - GlobeNewswire
    Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
    Strategic collaboration and licensing agreement further strengthens Galapagos’ growing early-​stage pipeline in oncology precision medicine Collaboration leverages Galapagos’ ...
    02.01.24 - GlobeNewswire
    Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
    Transaction expected to close in the first quarter of 2024, subject to customary closing conditions Michele Manto, Galapagos’ Chief Commercial Officer, to join Alfasigma Mechelen, ...
    19.12.23 - GlobeNewswire
    Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
    Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 ...
    09.12.23 - GlobeNewswire
    Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
    Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe ...
    07.12.23 - GlobeNewswire
    Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
    Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ...
    02.11.23 - GlobeNewswire
    Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
    First nine months 2023 key financials: Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financial investments of €3.8 billion at 30 September ...
    30.10.23 - GlobeNewswire
    Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
    Transaction would enable Galapagos to realize considerable annualized savings and accelerate its pipeline focused on developing transformational medicines Aims to preserve ...
    19.09.23 - GlobeNewswire
    Galapagos appoints Simon Sturge to its Board of Directors
    Mechelen, Belgium; 1 9 September 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 19 September 2023 , the Board of ...
    28.08.23 - GlobeNewswire
    Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus  
    GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor  GLPG3667 is currently in development for the treatment of inflammatory and ...
    03.08.23 - GlobeNewswire
    Galapagos announces first half-year 2023 financial results
    Half-year 2023 key financials Group revenues of €328.8 million Jyseleca® net sales of €54.3 million Cash and current financial investments of €3.9 billion on 30 June 2023 Full year ...
    15.06.23 - GlobeNewswire
    Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
    Mechelen, Belgium; 15 June 2023, 22:01 CET ; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of T had Huston as Chief ...
    12.06.23 - GlobeNewswire
    Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
    Mechelen, Belgium; 12 June 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 12 June 2023 , the Board of Directors co-...
    05.06.23 - GlobeNewswire
    Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress
    All 7 out of 7 eligible patients with relapsed/refractory c hronic l ymphocytic l eukemia ( rrCLL ) , with or without Richter’s T ransformation (RT) , responded to treatment (Objective ...

    Newssuche

    Videos

    newspaper
    18.04.24
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »